Key result
Systemic administration of α-GalCer in CVB3-infected mice reduced viral titres, ameliorated heart damage, and improved the disease course compared with untreated mice.
Why the study?
Does α-galactosylceramide prevent lethal myocarditis in mice infected with Coxsackievirus B3?
Does α-galactosylceramide prevent lethal myocarditis in mice infected with Coxsackievirus B3?
Systemic administration of α-galactosylceramide protects against lethal Coxsackievirus B3-induced myocarditis in mice by modulating the early anti-viral immune response.
Answers are grounded in this paper and cite their sources.
α-GalCer may protect against CVB3 myocarditis in mice; leaves open translation to human viral disease.
Myocarditis is an inflammation of the myocardium which often follows virus infections. Coxsackievirus B3 (CVB3), as a marker of the enterovirus group, is one of the most important infectious agents of virus-induced myocarditis. Using a CVB3-induced myocarditis model, we show that injection α-galactosylceramide (α-GalCer), a ligand for invariant natural killer (NK) T (iNK T) cells, can protect the mice from viral myocarditis. After the systemic administration of α-GalCer in CVB3 infected mice, viral transcription and titres in mouse heart, sera and spleen were reduced, and the damage to the heart was ameliorated. This is accompanied by a better disease course with an improved weight loss profile. Compared with untreated mice, α-GalCer-treated mice showed high levels of interferon (IFN)-γ and interleukin (IL)-4, and reduced proinflammatory cytokines and chemokines in their cardiac tissue. Anti-viral immune response was up-regulated by α-GalCer. Three days after CVB3 infection, α-GalCer-administered mice had larger spleens. Besides NK T cells, more macrophages and CD8(+) T cells were found in these spleens. Upon stimulation with phorbol myristate acetate plus ionomycin, splenocytes from α-GalCer-treated mice produced significantly more cytokines [including IFN-γ, tumour necrosis factor-α, IL-4 and IL-10] than those from untreated mice. These data suggest that administration of α-GalCer during acute CVB3 infection is able to protect the mice from lethal myocarditis by local changes in inflammatory cytokine patterns and enhancement of anti-viral immune response at the early stage. α-GalCer is a potential candidate for viral myocarditis treatment. Our work supports the use of anti-viral treatment early to reduce the incidence of virus-mediated heart damage.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2010) studied Coxsackievirus B3 (CVB3)-induced myocarditis. α-galactosylceramide (α-GalCer) vs. Untreated mice was evaluated on Viral transcription and titres, heart damage, and disease course. Systemic administration of α-GalCer in CVB3-infected mice reduced viral titres, ameliorated heart damage, and improved the disease course compared with untreated mice.
Synapse has enriched 10 related papers. Consider them for comparative context: